Lisa Cook sues Trump over firing attempt, emergency hearing set
Tomohiro Higa, SVP, Finance at Tenaya Therapeutics , Inc. (NASDAQ:TNYA), sold a total of 2,962 shares of common stock on August 18, 2025. The sales were executed in three separate transactions, with the price per share at $1.253. The price range for these sales was between $1.18 and $1.32. The stock has shown significant momentum recently, with a remarkable 66% return over the past week, trading near its current price of $1.26.
The first sale involved 523 shares, totaling $655. The second transaction saw 717 shares sold, amounting to $898. The final transaction involved the sale of 1,722 shares, which totaled $2157.
These sales were executed to cover tax withholding obligations related to the vesting of restricted stock units. The restricted stock units were awarded on February 15, 2023, February 23, 2024, and January 24, 2025.
Following these transactions, Higa directly owns 95,338 shares of Tenaya Therapeutics, Inc., including restricted stock units that will be issued upon vesting. With a market capitalization of $204.5 million and strong analyst support (consensus rating of 1.38 out of 5), the company shows promise despite current challenges. Discover more insights and 12 additional ProTips with InvestingPro.
In other recent news, Tenaya Therapeutics has made significant progress in its clinical trials for cardiovascular gene therapies. The company announced positive safety endorsements from independent Data Safety and Monitoring Boards for its MyPEAK-1 and RIDGE-1 trials. These approvals allow Tenaya to proceed with expansion cohorts for TN-201 and to escalate dosing levels for TN-401. Additionally, Tenaya has completed enrollment in both dose cohorts of the MyPEAK-1 Phase 1b/2 clinical trial for TN-201, which targets hypertrophic cardiomyopathy. The company also reported dosing the first patient in Cohort 2 of the RIDGE-1 Phase 1b clinical trial for TN-401, aimed at treating arrhythmogenic right ventricular cardiomyopathy. These developments mark important milestones in Tenaya’s ongoing efforts to advance its gene therapy programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.